News & views
A collection of stories about our people, our research, and global health.
Browse all news
10 min read
Neglected disease R&D: A smart investment for a safer, stronger United Kingdom
As we publish our report into the impact of the UK's funding of global health R&D, Dr Celine Aerts argues that cutting funding is a short-sighted decision.
10 min read
The value of vaccines: what to do in the face of funding cuts which put decades of progress at risk
In this blog, Dr Nick Chapman urges us to prepare for a future that doesn’t look like the past
-404x606.webp)
5 min read
5 top tips to make your work easier
We've redesigned our website to give you fast and easy access to information you need
5 min read
Making a stand for global health
Our CEO, Dr Nick Chapman, responds to the US withdrawal from global health programmes and shares how Impact Global Health is leading conversations to shape a sustainable future.
-404x303.webp)
10 min read
In turbulent times, Europe must double down on its investments in Global Health R&D
Vanessa Candeais shows how investment in global public goods, global solidarity, and equity is a strategic necessity for Europe, providing clarity and leadership for the world and for its own future.
%20(1)-404x211.webp)
10 min read
Smart Decisions launch event notes
We share the summary notes and slides from the launch of the Smart Decisions: the G-FINDER 2024 Neglected Disease R&D report
5 min read
Opening: Global Advisory Council Member
We're seeking a Global Advisory Council Member to grow our impact. Applications close February 28.
-404x269.webp)
20 min read
Outbreak preparedness: Have we learned from COVID-19?
Our Director, Science & Policy, Dr Lindsay Keir, looks at the lessons of COVID-19 and asks whether our response to the recent mpox outbreak shows that we have learned?
5 min read
Monoclonal antibodies: an untapped resource for global health
Dr Alex Asamoah Ankomah, our Technical Officer in the Science & Policy Advisory team, examines the transformative potential of monoclonal antibodies (mAbs) in combatting infectious diseases and highlights their promise despite challenges in cost and access, particularly in LMICs
